Background: The main goal of the Third Stroke Registry in Tartu was to determine the incidence and 28-day case-fatality rates for first-ever stroke in an Estonian population. Methods: The data collection started on 01.12.2001. All patients with first-ever stroke living in Tartu were registered. Results: During the first year, 234 first-ever stroke cases were registered. The incidence rate of first-ever stroke age-standardised to the European population was 195/100,000, 214 (95% CI, 185–243) for men and 181 (95% CI, 155–208) per 100,000 for women. Sixty-eight patients (29%) died within 28 days of stroke onset. Conclusions: The incidence and 28-day case-fatality rate of stroke in Estonia are high compared to other countries. It might be related to higher risk factor prevalence, stress and socioeconomic status.

1.
Sudlow CLM, Warlow CP: Comparing stroke incidence worldwide: What makes the studies comparable? Stroke 1996:550–558.
2.
Mihalka L, Smolanka V, Bulecza B, Mulesa S, Bereczki D: A population study of stroke in West-Ukraine. Stroke 2001;32:2227–2231.
3.
Wolf CDA, Giroud M, Kolomisky-Rabas P, Dundas R, Lemesle M, Heuschmann P, Rudd A: Variations in stroke incidence and survival in 3 areas of Europe. Stroke 2000;31:2074–2079.
4.
Vemmos KN, Bots ML, Tsibouris PK, Zis VP, Grobbee DE, Stranjalis GS, Stamatelopoulos S: Stroke incidence and case-fatality in southern Greece. Stroke 1999;30:36–70.
5.
Kõrv J, Roose M, Kaasik AE: Stroke registry of Tartu, Estonia, from 1991 through 1993. Cerebrovasc Dis 1997;7:154–162.
6.
Zupping R, Roose M: Epidemiology of cerebrovascular disease in Tartu, Estonia, USSR, 1970 through 1973. Stroke 1976;7:187–190.
7.
Available at http://www.stat.ee.
8.
Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, and the TOAST Investigators: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke 1993;24:35–41.
9.
Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, von Stockert TR: A prospective community-based study of stroke in Germany – the Erlangen Stroke Project (ESPro). Stroke 1998;29:2501–2506.
10.
Carolei A, Marini C, Di Napoli M, Di Gianfilippo G, Santalucia P, Baldassarre M, De Matteis G, Di Orio F: High stroke incidence in the prospective community-based L’Aquila registry (1994–1998). Stroke 1997;28:2500–2506.
11.
Ellekjaer H, Holmen J, Indredavik B, Terent A: Epidemiology of stroke in Inherred, Norway, 1994 to 1996. Stroke 1997;28:2180–2184.
12.
Johansson B, Norrving B, Lindgren A: Increased stroke incidence in Lund-Orup, Sweden, between 1983 to 1985 and 1993 to 1995. Stroke 2000;31:481.
13.
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU: Epidemiology of ischemic stroke subtypes according to TOAST criteria. Stroke 2001;32:2735–2740.
14.
Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC: Risk factors, outcome and treatment in sub-types of ischemic stroke: The German stroke databank. Stroke 2001;32:2559–2566.
15.
Petty GW, Brown RD, Whisnant JP, Sicks JD, O’Fallon WH, Wiebers DO: Ischemic stroke subtypes: A population-based study of incidence and risk factors. Stroke 1999;30:2513–2516.
16.
Jakovljević D, Sarti C, Sivenius J, Torppa J, Mähönen M, Immonen-Räihä P, Kaarsalo E, Alhainen K, Kuulasmaa K, Tuomilehto J, Puska P, Salomaa V: Socioeconomic status and ischemic stroke. The FINMONICA Stroke Register. Stroke 2001;32:1492–1498.
17.
Truelsen T, Nielsen N, Boysen G, Gronbaek M: Self-reported stress and risk of stroke. The Copenhagen City Heart Study. Stroke 2003;34:856–862.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.